The distinction that matters: Identifying a gene associated with risk is not the same as proving it causes every case, predicting an individual's diagnosis, or developing a treatment. The study's 36 high-confidence genes are statistical findings about rare genetic risk—not 36 available clinical targets.
What was discovered?
The paper, published in Nature Neuroscience on September 1, 2026 and highlighted by UC San Francisco on October 14, examined whole-exome sequencing data from 3,964 people with obsessive-compulsive disorder (OCD), chronic tic disorders (including Tourette syndrome), or both.
The dataset included 2,418 parent–child trios, allowing researchers to investigate newly arising (de novo) variants, and other affected participants. The team looked for uncommon variants predicted to damage protein function, comparing case patterns against control data. Across the OCD-specific, tic-specific and combined analyses, 36 genes met the authors' high-confidence statistical criteria; four had been identified in earlier comparable work.
36 high-confidence risk genes
Not every gene is relevant to every person with OCD or tics. The finding points to genetic risk distributed across biological pathways, rather than one universal cause.
Shared—and distinct—biology
Some rare-risk signals overlap with autism, intellectual or developmental disability, and schizophrenia research. Overlap does not mean these are the same condition, or that one diagnosis inevitably becomes another.
Brain development matters
Expression analyses highlighted prenatal and postnatal cortical regions, striatum, and cerebellum. These patterns help prioritize scientific hypotheses; they are not a brain scan that diagnoses OCD or Tourette.
Discovery, not prediction
Most people with OCD or tics will not be explained by one rare variant from this study. The authors did not validate a screening panel, calculate individual prognosis, or test a gene-targeting treatment.
Why do OCD and Tourette syndrome sometimes occur together?
OCD involves intrusive thoughts and repetitive actions or mental rituals; tics are sudden, repeated movements or sounds that can be preceded by uncomfortable urges. Some people experience both, but clinical assessment must still distinguish a tic from a compulsion, sensory distress or another repetitive behavior. Researchers are studying how overlapping genes and brain circuits may help explain co-occurrence.
Shared genetic risk is one piece of a much larger picture that includes development, environment and individual experience. Neither a diagnosis nor support needs can be inferred from a gene list alone.
What is established care today?
For OCD: exposure and response prevention
ERP, a specialized form of cognitive behavioral therapy, is supported by clinical evidence for OCD. Medication may also be appropriate based on age, symptoms, preferences and clinician assessment.
OCD supports and treatment evidence →For troublesome tics: CBIT
Comprehensive Behavioral Intervention for Tics is an evidence-based option that helps many people reduce tic-related impairment. Tics are not voluntary misbehavior, and not everyone needs treatment.
Tourette and tic support →For overlapping concerns: coordinated assessment
Ask for evaluation of OCD, tics, anxiety, ADHD and other co-occurring conditions when relevant. Different needs may require different supports, not one intervention for every symptom.
For daily life: functional goals
Measure comfort, relationships, learning, participation, independence and distress—not only a symptom count. A family or adult's own priorities belong in care planning.
Frequently asked questions
Should we order genetic testing because of this paper?
Not solely because of this study. It does not establish a routinely useful OCD or Tourette genetic test or show that testing these genes will choose an effective medication. Where a person also has developmental differences or other medical findings, a qualified clinician or genetic counselor can explain existing indications for clinical genetic evaluation.
Does a risk gene mean someone will develop OCD or Tourette syndrome?
No. Group-level rare variant associations do not determine an individual's diagnosis, future symptoms or need for treatment. Risk is not destiny.
Are gene therapies now available for OCD or tics?
No. The research points toward possible future biological targets; it does not report a successful gene-based treatment, clinical trial or regulatory authorization for these conditions.
Questions worth asking a specialist
- Which repetitive experiences are tics, which are OCD compulsions, and which may involve something else?
- Which evidence-based treatments fit the person's current priorities and level of impairment?
- Do any additional developmental or medical findings warrant a clinical genetics referral under current standards?
- How should our care plan address both symptom relief and everyday participation?
Original sources and editorial status
- Wang B et al. Whole-exome sequencing in individuals with obsessive–compulsive disorder and chronic tic disorders identifies 36 large-effect risk genes. Nature Neuroscience, September 1, 2026.
- UCSF Psychiatry — October 14, 2026 research announcement
- NIMH — OCD and evidence-based treatments
- CDC — Tourette syndrome treatment and CBIT
Reviewed October 16, 2026. This is educational reporting, not a genetic evaluation, diagnosis, or medical recommendation. Independent clinical review of NeuroCoach content remains pending.